New Asia Expansion For BioNTech As It Builds On Global Success
Singapore Wins Out
Executive Summary
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.
You may also be interested in...
BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.